<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01315301</url>
  </required_header>
  <id_info>
    <org_study_id>SWE-2007-270</org_study_id>
    <nct_id>NCT01315301</nct_id>
  </id_info>
  <brief_title>Optimal Time to Initiate Antiretroviral Therapy in HIV &amp; TB Coinfected Adults Being Treated for Tuberculosis</brief_title>
  <acronym>TB-HAART</acronym>
  <official_title>Randomized Clinical Trial to Determine the Most Appropriate Time to Start HIV Treatment in HIV &amp; TB Coinfected Adults Being Treated for Tuberculosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Addis Ababa University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study is to determine optimal time to initiate anti-retroviral therapy in HIV/TB&#xD;
      co-infected patients who recently started treatment for Tuberculosis by comparing immediate&#xD;
      versus deferred initiation of HAART.&#xD;
&#xD;
      The study will address the following questions;&#xD;
&#xD;
        -  Is it possible to reduce mortality rate and increase survival by early initiation of&#xD;
           HAART during TB treatment with out compromising for adverse drug reaction, toxicity and&#xD;
           immune reconstitution syndrome?&#xD;
&#xD;
        -  What is the risk/ benefit ratio between immediate versus deferred initiation of HAART&#xD;
           during TB treatment with respect to safety/efficacy of TB and HIV co-treatment?&#xD;
&#xD;
        -  When is the most appropriate time to start HAART during TB treatment?&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study intends to determine the optimal time to start ART by comparing three treatment&#xD;
      strategies of ART initiation in HIV/TB co-infected patients. Four hundred fifty newly&#xD;
      diagnosed HIV infected patients with active TB and CD4 cell count &lt; 200 cells/mm3 will be&#xD;
      prospectively recruited to be assigned randomly in parallel into one of the three treatment&#xD;
      groups (n=150 in each group) and HAART will be started at different time points as described&#xD;
      below with extensive counseling and adherence support.&#xD;
&#xD;
        -  Arm-A (Immediate Treatment Group): Receipt of antiretroviral therapy one week after&#xD;
           starting anti-TB treatment.&#xD;
&#xD;
        -  Arm-B (Deferred Treatment Group-1): Antiretroviral therapy will be initiated at the 4th&#xD;
           week of starting anti-TB treatment (in the middle of the intensive phase TB treatment).&#xD;
&#xD;
        -  Arm-C (Deferred Treatment Group-2): Antiretroviral therapy will be initiated at the 8th&#xD;
           week of starting anti-TB treatment (after completion of the intensive phase of TB&#xD;
           treatment).&#xD;
&#xD;
      Study Design: Interventional, prospective, randomized, open-label three-armed trial with no&#xD;
      placebo, Active control, parallel assignment, safety and efficacy study.&#xD;
&#xD;
      Study population: Previously untreated HIV-infected adult patients with TB and CD4 cell&#xD;
      counts &lt; 200/mm3 at the time of TB diagnosis.&#xD;
&#xD;
      Expected Total Enrollment = 450&#xD;
&#xD;
      Treatment: Patients will receive first-line preferred regimen for patients with TB and HIV&#xD;
      coinfection (rifampicin containing short course TB treatment and efavirenz-containing HAART&#xD;
      regimen. The intensive phase of anti-TB therapy consists of 2 months treatment with&#xD;
      Rifampicin, Isoniazid, Pyrazinamide and Ethambutol followed by the continuation phase with&#xD;
      Isoniazid and Rifampicin daily for 4 months under Directly Observed Therapy (DOTS). After the&#xD;
      initiation of TB treatment, patients in Arm-A, Arm-B and Arm-C will start EFV-containing&#xD;
      HAART regimen (efavirenz + Lamivudine (3TC) + Stavudine (d4T) after one week, in the&#xD;
      middle(at 4th week) and at the end (8th week) of the intensive phase TB treatment&#xD;
      respectively. Primar prophylaxis with cotrimoxazole will be offered to all patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2008</start_date>
  <completion_date type="Anticipated">March 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mortality</measure>
    <time_frame>24 weeks</time_frame>
    <description>all cause mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tuberculosis-Immune Reconstitution Inflammatory Syndrome</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New AIDS defining clinical events</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug Induced Liver toxicity</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic success</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of patients with Virologic success defined as achieving a viral load of &lt; 50 HIV-1 RNA copies/mL within 6 months of starting therapy</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Acquired Immunodeficiency Syndrome</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Arm-A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immediate Treatment Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm-B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Deferred Treatment Group-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm-C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Deferred Treatment Group-2</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Comparison of different treatment strategies</intervention_name>
    <description>600 mg efavirenz based HAART initiated one week after starting rifampicin based short course anti tuberculosis treatment.</description>
    <arm_group_label>Arm-A</arm_group_label>
    <other_name>Treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Comparison of different treatment strategies</intervention_name>
    <description>600 mg efavirenz based HAART initiated four weeks after starting rifampicin based short course anti tuberculosis treatment</description>
    <arm_group_label>Arm-B</arm_group_label>
    <other_name>Treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Comparison of different treatment strategies</intervention_name>
    <description>600 mg efavirenz based HAART initiated eight weeks after starting rifampicin based short course anti tuberculosis treatment.</description>
    <arm_group_label>Arm-C</arm_group_label>
    <other_name>Treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed ART naive HIV infected patients and age &gt; 18 years old&#xD;
&#xD;
          -  Newly diagnosed smear +ve PTB cases (abnormal CXR and at least one sputum sample +ve&#xD;
             for AFB)&#xD;
&#xD;
          -  Newly diagnosed smear -ve PTB cases (CXR consistent with active TB plus at least two&#xD;
             sputum specimens negative for AFB and decision by the physician to treat for TB or&#xD;
             smear negative for AFB but culture positive cases)&#xD;
&#xD;
          -  Tissue biopsy or FNAC results consistent with the diagnosis of tuberculosis&#xD;
&#xD;
          -  CD4 cell count &lt; 200/mm3 at the time of TB diagnosis&#xD;
&#xD;
          -  Residence in Addis Ababa, Ethiopia&#xD;
&#xD;
          -  Ability to give signed written/thumb sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy and breast-feeding women&#xD;
&#xD;
          -  Patients who received anti TB therapy with in the past two years&#xD;
&#xD;
          -  Patients who have previous treatment experience with antiretroviral therapy&#xD;
&#xD;
          -  Severely ill patients Karnofsky performance status score &lt; 40&#xD;
&#xD;
          -  Baseline Hgb &lt; 8 gms/dL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eleni Aklillu, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Krolinska Institutet, Stockholm, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wondwossen Amogne, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Addis Ababa University, Addis Ababa, Ethiopia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wondwossen Amogne, MD</last_name>
    <phone>+251911406179</phone>
    <email>wonamogne@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eleni Aklillu, PhD</last_name>
    <phone>+46735116131</phone>
    <email>Eleni.aklillu@ki.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tikur Anbessa (Black Lion) Hospital</name>
      <address>
        <city>Addis Ababa</city>
        <zip>P.O.Box 9086</zip>
        <country>Ethiopia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wondwossen Amogne, MD</last_name>
      <phone>+2519114046179</phone>
      <email>wonamogne@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Eleni Aklillu, PhD</last_name>
      <phone>+47735116131</phone>
      <email>eleni.aklillu@ki.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Ethiopia</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>March 14, 2011</study_first_submitted>
  <study_first_submitted_qc>March 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2011</study_first_posted>
  <last_update_submitted>March 14, 2011</last_update_submitted>
  <last_update_submitted_qc>March 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Eleni Aklillu,PhD, Associate Professor</name_title>
    <organization>Karolinska Institutet, Stockholm, Sweden</organization>
  </responsible_party>
  <keyword>Efavirenz</keyword>
  <keyword>Rifampicin</keyword>
  <keyword>HAART</keyword>
  <keyword>Anti Tuberculosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

